Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 6/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 15/20 | 0.55 |
| ▸ | EGLN3 | Q9H6Z9 | 5/20 | 0.55 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.55 |
| ▸ | VEGFA | P15692 | 5/20 | 0.48 |
| ▸ | FLT1 | P17948 | 4/20 | 0.48 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25234042 | 1.00 | EGLN2 (0.56) | EGLN2EGLN1EGLN3FTOVEGFA | |
| SCHEMBL25233283 | 0.92 | EGLN1 (0.60) | EGLN2EGLN1EGLN3FTOVEGFA | |
| SCHEMBL25274411 | 0.89 | EGLN1 (0.71) | EGLN2EGLN1EGLN3FTOVEGFA | |
| SCHEMBL25233066 | 0.89 | FTO (0.71) | EGLN2EGLN1EGLN3FTOVEGFA | |
| SCHEMBL30457540 | 0.88 | EGLN1 (0.58) | EGLN2EGLN1EGLN3FTOVEGFA | |
| SCHEMBL25230450 | 0.88 | EGLN1 (0.58) | EGLN2EGLN1EGLN3FTOVEGFA | |
| SCHEMBL30458209 | 0.86 | EGLN1 (0.54) | EGLN2EGLN1EGLN3FTOVEGFA | |
| SCHEMBL25276548 | 0.86 | EGLN1 (0.54) | EGLN2EGLN1EGLN3FTOVEGFA | |
| SCHEMBL25283106 | 0.86 | EGLN2 (0.56) | EGLN2EGLN1EGLN3FTOVEGFA | |
| SCHEMBL31051003 | 0.86 | EGLN2 (0.56) | EGLN2EGLN1EGLN3FTOVEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4447963-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-118715015-A | Selective PHD1 inhibitor compounds, compositions and methods of use | 阿克比治疗有限公司 | 2024-09-27 | — | — | CN | disclosed |
| WO-2023111990-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |